IP Library Granted Patent US 10,238,604
Granted Patent B2
US 10,238,604 · App. 14/570,673 · Granted Mar 26, 2019

Controlled activation ingestible identifier

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,604
App. No.
14/570,673
Granted
Mar 26, 2019
Kind
B2
Abstract

Controlled activation identifiers for use in ingestible compositions, such as pharma-informatics enabled compositions, are provided. The identifiers include a controlled activation element that provides for activation of the identifier in response to the presence of a predetermined stimulus at a target site of interest. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.

Claims (25)

1. A pharmaceutical composition comprising:

a pharmaceutically active agent;

a controlled activation identifier configured to transmit a signal upon contact with a target site of a body, wherein the controlled activation identifier comprises:

first and second materials with dissimilar electrochemical properties;

a dried conductive medium precursor; and

a plurality of protective layers comprising:

a first layer configured to prevent mechanical damage to the controlled activation identifier;

a second layer configured to dissolve at a target pH; and

a third layer configured to control exposure of the dried conductive medium precursor to the target site.

2. The pharmaceutical composition according to claim 1 , wherein the controlled activation identifier is configured to transmit the signal upon contact with a target site fluid present at the target site.

3. The pharmaceutical composition according to claim 2 , wherein the signal is consistent regardless of variations in properties of the target site fluid.

4. The pharmaceutical composition according to claim 3 , wherein the first and second materials are configured to create a voltaic cell when in contact with an electrically conductive fluid at the target site, wherein the voltaic cell supplies power to the controlled activation identifier.

5. The pharmaceutical composition according to claim 1 , wherein the dried conductive medium precursor is configured to produce a conductive medium that conductively couples the first and second materials upon the dried conductive medium precursor being wetted, and wherein the controlled activation identifier transmits the signal when the dried conductive medium couples the first and second materials.

6. The pharmaceutical composition according to claim 1 , wherein the third layer comprises a semipermeable membrane.

7. The pharmaceutical composition according to claim 1 , wherein the third layer comprises a solid barrier comprising a fluid flow path.

8. The pharmaceutical composition according to claim 7 , wherein the flow path is a capillary fluid flow path.

9. The pharmaceutical composition according to claim 8 , wherein the capillary fluid flow path comprises at least one surface, the at least one surface comprising a surface treatment configured to enhance hydrophilic fluid flow through the capillary flow path.

10. The pharmaceutical composition according to claim 1 , wherein the controlled activation identifier comprises a polymeric coating configured to dissolve upon contact with a fluid in a time delayed manner.

11. The pharmaceutical composition according to claim 10 , wherein the polymeric coating is configured to dissolve over a time period, the time period corresponding to a time required for a target site fluid pH or conductivity to reach a target value following ingestion of an external fluid.

12. The pharmaceutical composition according to claim 1 , wherein the controlled activation identifier comprises an integrated circuit.

13. The pharmaceutical composition according to claim 12 , wherein the controlled activation identifier comprises at least one transmitter.

14. The pharmaceutical composition according to claim 13 , wherein the transmitter comprises an electrode.

15. The pharmaceutical composition according to claim 1 , wherein the composition is an oral formulation.

16. The pharmaceutical composition according to claim 15 , wherein the oral formulation is a solid oral formulation.

17. The pharmaceutical composition according to claim 16 , wherein the solid formulation is a pill.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: PROTEUS DIGITAL HEALTH INC.,
To: OTSUKA AMERICA PHARMACEUTICAL, INC.
Reel/Frame 068980/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: OTSUKA AMERICA PHARMACEUTICAL, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 068980/0277 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2015
From: HAFEZI, HOOMAN; ROBERTSON, TIMOTHY; COLLIOU, OLIVIER
To: PROTEUS BIOMEDICAL, INC.
Reel/Frame 034902/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2015
From: ZDEBLICK, MARK
To: PROTEUS DIGITAL HEALTH, INC.
Reel/Frame 034902/0738 →
CHANGE OF NAME Recorded Feb 6, 2015
From: PROTEUS BIOMEDICAL, INC.
To: PROTEUS DIGITAL HEALTH, INC.
Reel/Frame 034914/0323 →